Blog
RSS FeedPosted by Michael Wonder on 06 Apr 2020
COVID-19 update: daily roundup 6 April 2020
6 April 2020 - The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort ...
Posted by Michael Wonder on 06 Apr 2020
A coronavirus casualty: delay in comprehensive drug pricing legislation
6 April 2020 - As numbers of new cases of coronavirus mount as well as an increasing death toll, the ...
Posted by Michael Wonder on 06 Apr 2020
EU authorities agree new measures to support availability of medicines used in the COVID-19 pandemic
6 April 2020 - The continued availability of medicines, in particular those used for patients with COVID-19, is of critical ...
Posted by Michael Wonder on 06 Apr 2020
Amendments to the new restrictions on prescribing hydroxychloroquine for COVID-19
6 April 2020 - On 24 March 2020, new restrictions came into effect limiting the health practitioners who could initiate ...
Posted by Michael Wonder on 06 Apr 2020
Medicines Australia and the Generic and Biosimilar Medicines Association granted interim authorisation by the ACCC
3 April 2020 - In an important collaborative step, Medicines Australia and the Generic and Biosimilar Medicines Association have today ...
Posted by Michael Wonder on 06 Apr 2020
Trump pushed health officials to make anti-malaria drugs available as coronavirus treatment: report
4 April 2020 - President Trump pushed health health officials to make anti-malaria drugs available to treat the coronavirus although ...
Posted by Michael Wonder on 05 Apr 2020
Canada takes cautious approach to unapproved COVID-19 drugs, as others prescribe wide use
5 April 2020 - 'One perspective is "We’re in a time of desperation and let’s throw anything we can at it." ...
Posted by Michael Wonder on 05 Apr 2020
Why FDA’s issuance of EUAs are not ‘approvals’ and why that matters
3 April 2020 - You may have read that some drugs are now “approved” to treat COVID-19, or as the ...
Posted by Michael Wonder on 04 Apr 2020
Swiss Government expands powers to force firms to make supplies to fight COVID-19
3 April 2020 - The Swiss government on Friday boosted its powers to order companies to raise production of critical ...
Posted by Michael Wonder on 03 Apr 2020
EMA provides recommendations on compassionate use of remdesivir for COVID-19
3 April 2020 - During an extraordinary virtual meeting held on 2 April 2020, EMA’s CHMP gave recommendations on how ...
Posted by Michael Wonder on 03 Apr 2020
International regulators discuss available knowledge supporting COVID-19 medicine development
3 April 2020 - On 2 April, regulators from around the world joined the second workshop on COVID-19 organised by ...
Posted by Michael Wonder on 02 Apr 2020
Biosimilars could disappear if the Supreme Court overturns the ACA
1 April 2020 - With the sense of urgency rightly focused on slowing or stopping the spread of COVID-19, it ...
Posted by Michael Wonder on 02 Apr 2020
EMA urges caution on malaria drugs' use for COVID-19 in absence of evidence
1 April 2020 - The European Union's drug regulator warned on Wednesday that two older malaria drugs being tested against ...
Posted by Michael Wonder on 01 Apr 2020
Coronavirus Treatment Acceleration Program
1 April 2020 - FDA has created a special emergency program for possible therapies, the Coronavirus Treatment Acceleration Program. ...
Posted by Michael Wonder on 01 Apr 2020
COVID-19: chloroquine and hydroxychloroquine only to be used in clinical trials or emergency use programmes
1 April 2020 - Chloroquine and hydroxychloroquine, two medicines currently authorised for malaria and certain autoimmune diseases, are being investigated ...